Physician profile
Hui Lin
NPI 1912617895
$7,578.26
in general payments reported to CMS, 2019-2025
27 companies · $2,940 in 2025
The $2,940 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,177 · 2024: $3,462 · 2025: $2,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,281 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,281.48 |
| Education | $296.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,208.68 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $762.21 | 2023-2025 | Tremfya |
| Incyte Corporation | $747.53 | 2023-2025 | Opzelura, Opzelura |
| Abbvie INC. | $716.69 | 2023-2025 | |
| Pfizer INC. | $640.21 | 2023-2025 | |
| Genzyme Corporation | $548.43 | 2024-2025 | |
| Dermavant Sciences, INC. | $467.99 | 2024 | Vtama |
| Lilly USA, LLC | $394.97 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $340.76 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $259.92 | 2024-2025 | Dupixent, Libtayo |
| Verrica Pharmaceuticals INC. | $212.76 | 2023-2024 | Ycanth |
| Amgen INC. | $159.34 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $155.90 | 2023-2025 | Hadlima, Vtama |
| Botanix Sb INC | $150.29 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $140.24 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $129.07 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $121.46 | 2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $116.70 | 2025 | Neffy |
| Ucb, INC. | $116.62 | 2024-2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $42.50 | 2025 | Koselugo |
| Fresenius Kabi USA, LLC | $25.18 | 2023 | |
| Sandoz INC. | $24.23 | 2024 | Hyrimoz |
| Almirall LLC | $23.37 | 2025 | Klisyri |
| Journey Medical Corporation | $22.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.51 | 2024 | Cyltezo |
| Sun Pharmaceutical Industries INC. | $14.00 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.92 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.